A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation

NCT05641493 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

COMBINATION_PRODUCT: HLX208+HLX10

Sponsor

Shanghai Henlius Biotech